laparoscopic kidney tumor enucleation. The tumor bed parenchyma of 15 mm beyond the pseudocapsule were continuously sectioned and examined to investigate the possible presence of tumor invasion or satellite lesions.
INTRODUCTION AND OBJECTIVES: Chronic kidney disease has significant implications on patient outcomes. Proteinuria along with glomerular filtration rate is increasing used as a marker for kidney disease. The relationship between pre-operative proteinuria and survival following nephrectomy is incompletely characterized. Herein, we evaluated the association of preoperative proteinuria with overall and cancer-specific survival in our institutional nephrectomy registry.
METHODS: We identified patients with clear cell renal cell carcinoma treated for curative intent from 1995 to 2010. Patients were categorized based on KDIGO (Kidney Disease Improving Global Outcomes) 2012 guidelines. Overall and cancer-specific survivals were evaluated using Kaplan-Meier methodology. Cox proportional hazards regression models were used to assess for variables associated with overall and cancer-specific mortality.
RESULTS: Between 1995 and 2010, 1,846 patients underwent radical or partial nephrectomy. Of these, 1,347 (73%) underwent preoperative predicted 24-hour urine protein testing. Patients with and without predicted 24-hour urine protein had no difference in overall survival (p¼0.73) or cancer-specific survival (p¼0.85). There were 804 (60%) patients classified with mild (<150 mg/day), 332 (25%) classified with moderate (150-500 mg/day), and 211 (16%) classified with severe proteinuria (>500 mg/day). Kaplan-Meier overall survival curves stratified by pre-operative proteinuria severity are depicted in the Figure  (p<0 INTRODUCTION AND OBJECTIVES: Emerging data from centers of excellence suggests that partial nephrectomy (PN) for cT1b and cT2a Renal Cell Carcinoma (RCC) are oncologically safe and may confer renal functional benefit. We sought to study trends in utilization and short term quality outcomes of PN among patients with cT1b and cT2a RCC using the National Cancer Database (NCDB).
METHODS: We identified 39,561 patients with localized cT1b or cT2a RCC who underwent PN from 2004-2013. Primary outcome was utilization of PN over time. Secondary outcomes included hospital length of stay (LOS, short hospitalization: 0-4 days), margin status and 30-day readmissions. Cochrane-Armitage test was used to describe trends over time. Multivariable (MVA) logistic regression models were used to investigate associations between tumor stage and outcomes.
RESULTS: The study consisted of 28,620 (72.3%) patients with cT1b and 10,941 (27.7%) with cT2a masses. Overall, 8,953 (22.6%) patients underwent PN. More patients with cT1b vs. cT2a tumors underwent PN (28.1% vs. 8.34%; p<0.01). PN increased over the study period (cT1b: 13.7% to 37.1%, p<0.01; cT2a: 3.2% to 11.0%, p<0.01; Figure) . For all PN, positive margin rates increased from 4.3% in 2004 to 6.8% in 2013, (p<0.01); 30-day readmission was not significantly changed (2.2% in 2004 to 5.1% in 2013, p¼0.76). Proportion of short LOS increased, from 51.6% in 2004 to 75.2% in 2013 (p<0.01). MVA for positive margins was notable for increasing age (OR 1.01, p¼0.012), year of diagnosis (OR 1.07, p¼0.01), and facility type (comprehensive community OR 1.362, p¼0.002, integrated network cancer program OR 1.53, p¼0.009, free standing cancer center program OR 3.44, p¼0.003). MVA for 30-day readmission demonstrated high Charlson score (OR 1.38, p¼0.046), and facility type (integrated network cancer program OR 0.56, p¼0.022) as being significant. On MVA, patients with cT2a tumors were no more likely than those with cT1b to require 30-day readmission (OR 0.86, p¼0.36) or have positive margins (OR 0.96, p¼0.75).
CONCLUSIONS: Utilization of PN for cT1b and cT2a renal mass has increased over time. While length of hospital stay has shortened and 30-day readmission rates are not significantly different, an increase in positive margin rates has been noted, with predictive factors including patient age and facility type. PN in cT2a does not confer increased risk compared to PN in cT1b RCC. Focused emphasis Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e957 and strategies to reduce positive margin rates in this higher risk population of localized renal masses should be considered. METHODS: A single-institutional retrospective analysis was implemented on 2329 patients who underwent radical or partial nephrectomy for non-metastatic RCC from 2000 to 2014. Enrolled patients were grouped into normal (BMI <23kg/m2, n¼705), overweight (BMI 23-24.9 kg/m2, n¼648), and obese (BMI ¼25kg/m2, n¼976) according to BMI cut-offs for Asian population. Outcomes of interest included recurrence free survival (RFS), overall survival (OS), and cancer-specific survival (CSS). Survival curves for each BMI category were estimated and compared using the Kaplan-Meier method with log-rank test. The impact of BMI as continuous or categorical variables on survival outcomes was assessed with multivariable Cox proportional hazard models.
RESULTS: Several clinico-pathological factors, including asymptomatic presentation, being female, lower transfusion rate, higher proportion of clear cell histology, and lower frequency of nodal invasion, were observed in association with obese group (all p<0.05). Obese group showed significantly better 5-year RFS (90.7% vs 84.9%, p<0.001), OS (91.8% vs 86.8%, p¼0.002), and CSS (94.8% vs 89.4%, p¼0.002) rates than normal patients. On multivariable analysis, BMI as continuous variable independently correlated with favorable RFS (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.89-0.97, p¼0.002), OS (HR 0.95; 95% CI 0.91-0.99, p¼0.033) and CSS (HR 0.91; 95% CI 0.86-0.97, p¼0.002). In addition, multivariable analysis revealed overweight (HR 0.57; 95% CI 0.37-0.87, p¼0.009) and obese patients (HR 0.58; 95% CI 0.39-0.87, p¼0.009) were associated with significantly reduced risk of RCC related death compared to normal patients.
CONCLUSIONS: Our data suggest overweight and obesity defined as increasing BMI are generally related to favorable survival outcomes after nephrectomy for non-metastatic RCC. Further basic research will be required to discover the biological mechanisms explaining the positive correlation between high BMI and improved RCC survival. Surgical Quality Improvement Program (NSQIP) database as a predictor of increased healthcare resource utilization (HRU) after elective minimally invasive radical nephrectomy (MIRN).
METHODS: The NSQIP database (2012 -2015) was used to identify patients with renal cell carcinoma who had elective MIRN. The primary outcome of interest was increased HRU, which was pre-defined as prolonged length of hospital stay (PLOS) (> 4 d), discharged to continued care (DCC), and unplanned readmission (UR) within 30 days of surgery. FFI was modified from the previously reported 11-item frailty index and based on 6 variables were not collected in recent NSQIP database possibly because of infrequent occurrence. FFI was calculated by scoring following items (full score of 6): diabetes (1 if on oral agents, 2 if on insulin), impaired functional status (1), chronic obstructive pulmonary disease (1), hypertension requiring medication (1), and congestive heart failure in 30 days before surgery (1). Patients were stratified into 4 groups by FFI (0, 1, 2, and ! 3) and outcomes were compared. Multivariable logistic regression was performed to determine whether FFI could independently predict increased HRU outcomes.
RESULTS: A total of 2,321 patients were included. Increased HRU outcomes stratified by FFI were shown in Figure 1 and there was increasing likelihood with increasing FFI. Multivariable logistic regression showed that FFI ¼ 2 (OR ¼ 1.96 [1.36-2.81], P <0.001) and FFI ! 3 (OR ¼ 3.10 [2.08-4.62], P <0.001) were independent predictors of overall increased HRU. When the outcomes of PLOS, DCC, and UR were analyzed separately, FFI ¼ 2 (OR ¼ 1.78, P ¼ 0.006 for PLOS, OR ¼ 4.61, P ¼ 0.008 for DCC, and OR ¼ 1.93, P ¼ 0.042 for UR) and FFI! 3 (OR ¼ 2.73, P < 0.001 for PLOS, OR ¼ 7.85, P < 0.001 for DCC, and OR ¼ 2.47, P ¼ 0.009 for UR) were still independently associated with each individual outcome.
CONCLUSIONS: The readily available and easily reproducible FFI correlates with increased HRU after MIRN. FFI might be a useful tool to patients, providers, and healthcare policy makers in terms of surgical safety as well as cost outcomes. Further studies are needed to validate our findings. varies based on clinical and pathologic features, while risk of noncancer death evolves as a function of age and comorbidities. Despite these differences in how these competing risks mature over time, current guidelines recommend surveillance based on stage alone. We therefore sought to develop risk adapted postoperative surveillance recommendations.
Source of Funding: None
METHODS: Patients with ccRCC managed surgically between 1990 and 2008 (n¼2,511) were identified from the Mayo Clinic Nephrectomy registry and risks of abdominal and chest recurrence estimated using accelerated failure-time (AFT) models by pathology stage (pT1a, pT1b, pT2, pT3/4, or pTanyN+). Similarly, risk of non-cancer death was estimated by age (<50, 51-59, 60-69, 70-79, and !80) and comorbidity index (CCI: e958 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
